Summary
The relationship between the plasma concentrations of bufuralol and its major hydroxymetabolite (Ro 3-7410) and β-blocking activity was studied in 10 patients with uncomplicated essential hypertension. Blood samples and haemodynamic data were obtained during rest and after a single-level exercise test on a bicycle cycloergometer, prior to and up to 32 h after administration of a single oral dose of bufuralol 30 mg. Bufuralol was rapidly absorbed, following a first-order process with a lag time. The calculated maximal plasma concentration ranged from 44.6 to 200.3 ng/ml. The half-life of bufuralol was 2.75±1.15 h (mean±SD). Up to 50% of the parent drug was transformed into Ro 3-7410, which showed less interpatient variability in concentration and a fairly constant half-life, which was three times longer than that of the parent drug. In general, the heart rate (HR) was slightly decreased, although 2/10 patients showed an initial increase. The resting HR returned to its pre-treatment level within 6 h, the exercise HR took up to 32 h to return to the pre-treatment level. The drug reduced both resting and exercise blood pressure (BP). The former was reduced from 153.0±14.2/93.5±8.5 to 134.5±14.0/77.0±6.8 mmHg (systolic/diastolic BP; mean±SD) with 6 h after treatment. Similarly, the exercise BP was reduced from 199.0±15.2/98.5±8.8 to 171.0±9.9/88.5±8.5 mmHg at the 6th h post-dosing. The BP values had not returned to their pre-treatment levels even 32 h after treatment. Thus, bufuralol and its metabolite Ro 3-7410 induced a long-lasting antihypertensive effect and inhibited the cardio-acceleratory effect of exercise, and there was a good correlation between the pharmacokinetic and pharmacodynamic behaviour of the drug.
Similar content being viewed by others
References
Rostan A (1978) Action du tolamolol et du bufuralol sur la pression artérielle et l'activité de la rénine plasmatique. Praxis 67: 27–35
Magometschnigg D, Bonelli J, Kaik G, Rameis H (1979) Hemodynamic changes in hypertensive patients at rest and during administration of bufuralol-HCl or propranolol. Int J Clin Pharmacol Biopharm 17: 334–340
Balant L, Francis RJ, Tschopp JM, Tinguely D, Estreicher J, Fabre J (1978) Pharmacocinétique du bufuralol chez l'homme. Pharm Acta Helv 53: 307–313
Balant L, Francis RJ, Tozer TN, Marmy A, Tschopp JM, Fabre J (1980) Influence of renal failure on the hepatic clearance of bufuralol in man. J Pharmacokinet Biopharm 8: 421–438
Dayer P, Balant L, Courvoisier F, Kupfer A, Kubli A, Gorgia A, Fabre J (1982) The genetic control of bufuralol metabolism in man. Eur J Drug Metabol Pharmacokinet 7: 73–77
Dentry JMR (1973) Exercise testing and training. In: Stenfert HE. Coronary heart disease. Kroene B. V., Leiden, p 21
Haefelfinger P (1980) Determination of bufuralol and its major metabolites in plasma by high-performance liquid chromatography. J Chromatogr 221: 327–335
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Eckert, M., Cocco, G., Strozzi, C. et al. Relationship between pharmacokinetic and pharmacodynamic behaviour of bufuralol and its metabolite Ro 3-7410 in hypertensive patients. Eur J Clin Pharmacol 24, 479–484 (1983). https://doi.org/10.1007/BF00609890
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00609890